These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14695824)

  • 1. Synthesis and structure-activity relationships of 5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine derivatives: novel arginine vasopressin antagonists.
    Cho H; Murakami K; Nakanishi H; Fujisawa A; Isoshima H; Niwa M; Hayakawa K; Hase Y; Uchida I; Watanabe H; Wakitani K; Aisaka K
    J Med Chem; 2004 Jan; 47(1):101-9. PubMed ID: 14695824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptor.
    Baraldi PG; Romagnoli R; Pavani MG; Nuñez Mdel C; Tabrizi MA; Shryock JC; Leung E; Moorman AR; Uluoglu C; Iannotta V; Merighi S; Borea PA
    J Med Chem; 2003 Feb; 46(5):794-809. PubMed ID: 12593659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
    Albright JD; Reich MF; Delos Santos EG; Dusza JP; Sum FW; Venkatesan AM; Coupet J; Chan PS; Ru X; Mazandarani H; Bailey T
    J Med Chem; 1998 Jul; 41(14):2442-4. PubMed ID: 9651149
    [No Abstract]   [Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
    Tsukamoto I; Koshio H; Kuramochi T; Saitoh C; Yanai-Inamura H; Kitada-Nozawa C; Yamamoto E; Yatsu T; Shimada Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2009 Apr; 17(8):3130-41. PubMed ID: 19321349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-aroyl-2,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepines.
    Albright JD; Delos Santos EG; Dusza JP; Chan PS; Coupet J; Ru X; Mazandarani H
    Bioorg Med Chem Lett; 2000 Apr; 10(8):695-8. PubMed ID: 10782666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and some pharmacological properties of new V1/V2 antagonists of arginine-vasopressin with structural changes at their N-terminals.
    Lammek B; Konieczna E; Wierzba T; Wang YX; Gavras H
    Pol J Pharmacol Pharm; 1992; 44(2):179-86. PubMed ID: 1409118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4,10-dihydro-5H-thieno[3,2-c][1]benzazepine derivatives and 9,10-dihydro-4H-thieno[2,3-c][1]benzazepine derivatives as orally active arginine vasopressin receptor antagonists.
    Aranapakam V; Albright JD; Grosu GT; Chan PS; Coupet J; Saunders T; Ru X; Mazandarani H
    Bioorg Med Chem Lett; 1999 Jul; 9(13):1733-6. PubMed ID: 10406632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
    Imada T; Cho N; Imaeda T; Hayase Y; Sasaki S; Kasai S; Harada M; Matsumoto H; Endo S; Suzuki N; Furuya S
    J Med Chem; 2006 Jun; 49(13):3809-25. PubMed ID: 16789738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-ben zoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives.
    Matsuhisa A; Kikuchi K; Sakamoto K; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):329-39. PubMed ID: 10212383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.
    Molinari AJ; Trybulski EJ; Bagli J; Croce S; Considine J; Qi J; Ali K; Demaio W; Lihotz L; Cochran D
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5796-800. PubMed ID: 17855087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
    Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
    Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.
    Tsukamoto I; Koshio H; Akamatsu S; Kuramochi T; Saitoh C; Yatsu T; Yanai-Inamura H; Kitada C; Yamamoto E; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2008 Nov; 16(21):9524-35. PubMed ID: 18835174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly potent and orally active non-peptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-y l)carbonyl]-2-phenylbenzanilide derivatives.
    Shimada Y; Taniguchi N; Matsuhisa A; Sakamoto K; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 2000 Nov; 48(11):1644-51. PubMed ID: 11086891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1A receptor by introduction of alkoxy groups.
    Shimada Y; Taniguchi N; Matsuhisa A; Yatsu T; Tahara A; Tanaka A
    Chem Pharm Bull (Tokyo); 2003 Sep; 51(9):1075-80. PubMed ID: 12951451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and pharmacological evaluation of novel fused thiophene derivatives as 5-HT2A receptor antagonists: molecular modeling study.
    El-Kerdawy MM; El-Bendary ER; Abdel-Aziz AA; El-wasseef DR; El-Aziz NI
    Eur J Med Chem; 2010 May; 45(5):1805-20. PubMed ID: 20149493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.
    Matsuhisa A; Taniguchi N; Koshio H; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):21-31. PubMed ID: 10705470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist.
    Tsukada J; Tahara A; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
    Vascul Pharmacol; 2005 Jan; 42(2):47-55. PubMed ID: 15722249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and receptor binding of new thieno[2,3-d]-pyrimidines as selective ligands of 5-HT(3) receptors.
    Modica MN; Romeo G; Salerno L; Pittalà V; Siracusa MA; Mereghetti I; Cagnotto A; Mennini T; Gáspár R; Gál A; Falkay G; Palkó M; Maksay G; Fülöp F
    Arch Pharm (Weinheim); 2008 Jun; 341(6):333-43. PubMed ID: 18535994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.